NCT00515528 2021-01-26
Vaccination Plus Ontak in Patients With Metastatic Melanoma
University of Chicago
Phase 2 Terminated
Clinical Trials
6 trialsNCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00117845 2019-11-19
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01773889 2018-04-10
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT01251952 2017-06-20
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT00726037 2016-09-29
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Loyola University
Phase 2 Terminated